Vevo
Airol Anne Ubas is a Research Scientist at Vevo Therapeutics since May 2023, with a solid foundation in research developed during an undergraduate tenure at Yale University School of Medicine from August 2021 to May 2023, where Airol focused on pancreatic cancer cell lines and potential biomarkers for under-represented patient groups. Prior experience includes a Preclinical and Translational PKPD internship at Genentech and a Protein Engineering Discovery internship at Sutro Biopharma, alongside various roles in education and mentorship, including serving as a Yale Ambassador and social media coordinator for Our Lady of the Visitacion School. Airol holds a degree in Molecular, Cellular, and Developmental Biology from Yale University, complemented by advanced training in molecular immunology and biomedical studies from prestigious institutions.
This person is not in any offices
Vevo
1 followers
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.